Where does Gregory Harriman work?

Gregory Harriman is Partner at BioAdvance.

What does Gregory Harriman invest in?

Gregory Harriman invests in Biotech.

What check size does Gregory Harriman write?

Gregory Harriman typically writes checks of $1.5M – $5M.

What boards does Gregory Harriman sit on?

Gregory Harriman holds tracked board seats at Annovis, GenPro, Immunome, Novira, Opsidio, Ribonova, Treventis.

Where did Gregory Harriman go to school?

Gregory Harriman studied at UC San Diego (M.D., Medicine); University of California, Berkeley.

Gregory Harriman

Investor

Partner at BioAdvance

Pennsylvania

Writes $1.5M – $5M checks · typically $3.3M

About

Physician-scientist and biomedical executive with 25+ years in academic medicine and the biopharma industry, having led drug and biologics development. Founded Main Line Ventures and sits on several BioAdvance portfolio boards.

Contact· self-published, not guessed

g•••@bioadvance.comreveal

Invests in

Biotech

Experience

Optimeos Life SciencesChief Medical Officercurrent2022 — presentUnited States
BioAdvance CapitalPartner, Chief Investment Officercurrent2021 — presentRadnor, Pennsylvania, United States
Main Line VenturesPresidentcurrent2006 — present
Senzo HealthDirectorcurrent2022 — present
Opsidio, LLCDirectorcurrent2017 — present
TreventisDirectorcurrent2012 — present
BioAdvanceVenture Partner2012 — 2021Radnor, PA
RIBONOVA INC.Director2016 — 2021
Genome Profiling, LLCDirector2017 — 2018
Robin Hood VenturesMember2010 — 2017
ImmunomeDirector2012 — 2017
Enzium, Inc.Director2015 — 2017
QR PharmaDirector2012 — 2014
Drexel UniversityResearch Professor, School of Biomedical Engineering, Science and Health Systems2010 — 2014
Novira TherapeuticsDirector2011 — 2012Radnor, PA
Johnson & JohnsonVice President2001 — 2009
CentocorExecutive Director1998 — 2001
IVAXMedical Director1996 — 1998
Baylor College of MedicineAssistant Professor of Medicine1991 — 1996Houston, Texas

Skills & more

Angel Investing3Business Development9Lifesciences21Biotechnology29Commercialization14Venture Capital16Medical Devices13Clinical Development9Technology Transfer7Healthcare4Start-ups23Immunology7

+12 more

OncologyEntrepreneurshipDrug DevelopmentHardware DiagnosticsDrug DiscoveryScienceClinical TrialsInfectious DiseasesStrategic PlanningPharmaceutical IndustryBiomedical EngineeringBiopharmaceuticals

From Gregory's professional profile.

Investments

Board seats

AnnovisGenProImmunomeNoviraOpsidioRibonovaTreventis

Per the firm's website.

Colleagues at BioAdvance

Adam Glasofer

Entrepreneur-in-Residence at BioAdvance

David Shin

Partner at BioAdvance

Frederick Jones

Advisory Partner at BioAdvance

Gayle Mineo

Office Management at BioAdvance

Jeff Edelson

Entrepreneur-in-Residence at BioAdvance

Jen Gilburg

Board of Directors; Deputy Secretary, Office of Technology & Entrepreneurship, PA DCED at BioAdvance

Jonathan Epstein

Board of Directors; Dean of the School of Medicine and EVP of the Health System, University of Pennsylvania at BioAdvance

Marie Lindner

Entrepreneur-in-Residence at BioAdvance

Frequently asked questions

Who is Gregory Harriman?: Physician-scientist and biomedical executive with 25+ years in academic medicine and the biopharma industry, having led drug and biologics development. Founded Main Line Ventures and sits on several BioAdvance portfolio boards.
Where does Gregory Harriman work?: Gregory Harriman is Partner at BioAdvance.
What does Gregory Harriman invest in?: Gregory Harriman invests in Biotech.
What check size does Gregory Harriman write?: Gregory Harriman typically writes checks of $1.5M – $5M.
What boards does Gregory Harriman sit on?: Gregory Harriman holds tracked board seats at Annovis, GenPro, Immunome, Novira, Opsidio, Ribonova, Treventis.
Where did Gregory Harriman go to school?: Gregory Harriman studied at UC San Diego (M.D., Medicine); University of California, Berkeley.